Gentile Marica, Centonza Antonella, Lovero Domenica, Palmirotta Raffaele, Porta Camillo, Silvestris Franco, D'Oronzo Stella
Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
"Casa Sollievo della Sofferenza" Onco-hematologic Department, Medical Oncology Unit, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy.
J Bone Oncol. 2020 Nov 5;26:100337. doi: 10.1016/j.jbo.2020.100337. eCollection 2021 Feb.
Breast cancer (BC) is the most frequent malignancy and the first cause of cancer-related death in women. The majority of patients with advanced BC develop skeletal metastases which may ultimately lead to serious complications, termed skeletal-related events, that often dramatically impact on quality of life and survival. Therefore, the identification of biomarkers able to stratify BC patient risk to develop bone metastases (BM) is fundamental to define personalized diagnostic and therapeutic strategies, possibly at the earliest stages of the disease. In this regard, the advent of "omics" sciences boosted the investigation of several putative biomarkers of BC osteotropism, including deregulated genes, proteins and microRNAs. The present review revisits the current knowledge on BM development in BC and the most recent studies exploring potential BM-predicting biomarkers, based on the application of omics sciences to the study of primary breast malignancies.
乳腺癌（BC）是女性中最常见的恶性肿瘤，也是癌症相关死亡的首要原因。大多数晚期乳腺癌患者会发生骨转移，这最终可能导致严重并发症，即骨相关事件，这些事件常常对生活质量和生存期产生重大影响。因此，识别能够对乳腺癌患者发生骨转移（BM）的风险进行分层的生物标志物，对于制定个性化的诊断和治疗策略至关重要，可能在疾病的最早阶段就需要这样做。在这方面，“组学”科学的出现推动了对几种乳腺癌骨嗜性假定生物标志物的研究，包括失调的基因、蛋白质和微小RNA。本综述基于将组学科学应用于原发性乳腺恶性肿瘤的研究，重新审视了目前关于乳腺癌骨转移发生发展的知识以及探索潜在骨转移预测生物标志物的最新研究。
